Abstract
Aims This study investigated a) whether the affective, chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), respiratory, and neurological Long COVID (LC) symptom domains are intercorrelated manifestations of an underlying construct, namely the LC phenome; and b) the predictive effects of clinical symptoms and biomarkers of the COVID-19 infectious phase on LC.
Methods This cohort study included 71 LC patients who had suffered from COVID-19 six months prior. The patients complied with the LC disease criteria set forth by the World Health Organization (WHO). We used the WHO symptom list to score the LC symptoms and assessed SARS-CoV-2 positivity using real-time reverse transcription-polymerase chain reaction (RT-PCR), white blood cell counts, anion gap, alanine transaminase (ALT) levels, paraoxonase 1 (PON1) activity and genotypes, total radical trapping potential of plasma (TRAP), and nitric oxide metabolites (NOx).
Results All four clinical LC subdomains are significantly intercorrelated, allowing for the extraction of a single latent construct encompassing affective, CFS/ME, respiratory, and neurological symptoms, labeled the physio-affective phenome of LC. The latter was strongly predicted by dyspnea and productive sputum, RT-PCR SARS-CoV-2 cycle threshold values, lower anion gap, and increased neutrophil percentage during the infectious phase. Other predictive biomarkers were lower ALT, TRAP, and NOx levels, and the PON1 QR192 over dominant gene model (protective).
Conclusions LC may be a clinically homogeneous disease characterized by highly intercorrelated affective, CFS, neurological, and respiratory subdomains. The physio-affective phenome and its domains are strongly predicted by biomarkers of acute infection and associated inflammation and oxidative stress.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the FF60 grant and Sompoch Endowment Fund from the Faculty of Medicine, MDCU to MM. CT, PS and NH were supported by the e-ASIA Joint Research Program (e-ASIA JRP) from the National Science and Technology Development Agency; Ratchadapisek Somphot Fund, Faculty of Medicine, Chulalongkorn University, grant number RA-MF 03/68.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research project (IRB number 114/64) was approved by the Institutional Review Board of Chulalongkorn University's institutional ethics board. All patients gave written informed consent prior to participation in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
dr.michaelmaes{at}hotmail.com, chawit.tun{at}gmail.com, lsemeao{at}gmail.com, paulimichelin10{at}gmail.com, dessamatsu{at}hotmail.com, fbrinholi{at}hotmail.com, sabbatini2011{at}hotmail.com, 18190727710{at}163.com, yokpim{at}gmail.com
Data Availability Statement
The dataset that was made and/or analyzed during this study will be available from the corresponding author (MM) once it has been fully used by the authors and a reasonable request has been made.
